Virpax Announces Results of Maximum Tolerated Dose Study for ProbudurBusiness Wire • 5 days ago
Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous...
Share to Feed
Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous...
Virpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.77...
Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous...
Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous...
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX Get Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 71,100...
Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous...